Ebolavirus BDBV(subtype Bundibugyo,strain Uganda 2007) Envelope Glycoprotein 1 (GP1) (Ebolavirus BDBV(subtype Bundibugyo,strain Uganda 2007) GP1) Ile 33 - Gln 304 (Accession # ACI28624) was produced in human 293 cells (HEK293) at ACROBiosystems.
Ebolavirus BDBV(subtype Bundibugyo,strain Uganda 2007) GP1 is fused with a polyhistidine tag at the C-terminus, and has a calculated MW of 31.8 kDa. The predicted N-terminus is Ile 33. DTT-reduced Protein migrates as 40-60 kDa in SDS-PAGE .
Less than 1.0 EU per μg of the Ebolavirus BDBV(subtype Bundibugyo,strain Uganda 2007) GP1 by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.
Contact us for customized product form or formulation.
See Certificate of Analysis for reconstitution instructions and specific concentrations.
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4oC); After reconstitution under sterile conditions for 3 months (-70oC).
EBOV encodes seven structural proteins: nucleoprotein (NP), polymerase cofactor (VP35), (VP40), GP, transcription activator (VP30), VP24, and RNA polymerase (L). GP protein contains 160-kDa envelope-attached glycoprotein (GP) and a 110 kDa secreted glycoprotein (sGP). GP is a class I fusion protein which assembles as trimers on viral surface and plays an important role in virus entry and attachment. Mature GP is a disulfide-linked heterodimer formed by two subunits, GP1 and GP2, which are generated from the proteolytical process of GP precursor (pre-GP) by cellular furin during virus assembly . GP1 is responsible for binding to the receptor(s) on target cells. Interacts with CD209/DC-SIGN and CLEC4M/DC-SIGNR which act as cofactors for virus entry into the host cell. GP2 acts as a class I viral fusion protein. GP1,2 mediates endothelial cell activation and decreases endothelial barrier function. sGP seems to possess an anti-inflammatory activity as it can reverse the barrier-decreasing effects of TNF alpha.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.